What is Elucidata?
Elucidata, founded in 2015 and based in Cambridge, MA, is a biomedical data company. It operates the Polly platform, which offers comprehensive data analysis services. These services include robust data storage, secure data transfer and file access, and detailed screening data management, catering to the complex needs of the life sciences industry. The company's focus on providing advanced analytical tools positions it as a key player in accelerating biomedical research and development.
How much funding has Elucidata raised?
Elucidata has raised a total of $21M across 2 funding rounds:
Other Financing Round
$5M
Series A
$16M
Other Financing Round (2021): $5M with participation from Hyperplane Venture Capital and IvyCap Ventures
Series A (2022): $16M led by IvyCap Ventures, Hyperplane Venture Capital, Eight Roads Ventures, and F-Prime Capital Partners
Key Investors in Elucidata
IvyCap Ventures
IvyCap Ventures is a venture capital firm founded in 2011, dedicated to supporting entrepreneurs from premier educational institutions in India. The firm invests in early to growth-stage startups across various sectors, including DeepTech, ConsumerTech, HealthTech, Fintech, EdTech, and SaaS, focusing on innovative technology-based products and services.
Hyperplane Venture Capital
Hyperplane Venture Capital is a seed stage firm based in Boston, Massachusetts. The firm partners with exceptional founders who are harnessing machine intelligence, sensor technology, and cloud computing to design solutions at the nexus of perception, communication, and insight.
Eight Roads Ventures
Eight Roads, headquartered in Kent, is a venture capital investment company specializing in real estate, venture, and growth businesses.
What's next for Elucidata?
The recent major strategic investment signals a pivotal phase for Elucidata, likely enabling the company to scale its operations, enhance its Polly platform's capabilities, and expand its market reach. This capital infusion is expected to fuel further innovation in biomedical data analysis, potentially leading to new product development and strategic partnerships. Elucidata's continued access to significant funding indicates strong investor confidence in its business model and its potential to disrupt the biomedical data landscape.
See full Elucidata company page
